Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis?

A: Johnson & Johnson, $135.11, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $364.8 billion; www.jnj.com), operates through three major businesses:

Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs;

Medical devices and diagnostics (35%) sells equipment for joint reconstruction and… Read More

Growth Stocks: Johnson & Johnson plans for a growth spurt

Growth Stocks: Johnson & Johnson plans for a growth spurt

Both revenue and earnings continue to grow for this leading maker of prescription drugs and consumer products. But still, there are risks.
JOHNSON & JOHNSON (symbol JNJ on New York; www.jnj.com) operates through three major businesses:
Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal… Read More

Q: Dear Pat: Johnson & Johnson seems to be one of those stocks I regularly hear about. Please, may I have your analysis?

A: Johnson & Johnson, $124.44, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $337.1 billion; www.jnj.com), operates through three major businesses:
Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs;
Medical devices and diagnostics (35%) sells equipment for joint reconstruction and… Read More

3 big risks to investing in drug stocks

Drug stocks can offer lots of potential for investor profit—but there are three major hurdles most drug makers face.
Investors often comment that we sometimes differ with the mainstream view on which stocks make good investments. That’s especially true with drug stocks.
The… Read More